85 results
Page 4 of 5
6-K
EX-99.2
3hb8xa1mub5
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
oqqu hoif6m1c
29 Apr 20
InflaRx Reports Full Year 2019 Financial & Operating Results
8:00am
6-K
EX-99.1
x81taxh 9t
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
EX-99.2
fxjt542ombmqkf
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
amywfkxt1lqf4z
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.3
jh4n5i
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
5szq3 it3
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
y3sun3q
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.3
gu8wn6jgny cgdtl
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.1
jw6c 6da6
14 Aug 19
Current report (foreign)
4:16pm
6-K
EX-99.1
sscmgy ac77
18 Jul 19
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
4:12pm
6-K
EX-99.1
o4hxh554eh6b4 n6
13 Jun 19
Current report (foreign)
9:00am
6-K
EX-99.1
uw7eb5vd3aa5q033li
23 May 19
Current report (foreign)
8:00am
20-F/A
l2h vd1upniabv
29 Mar 19
Annual report (foreign) (amended)
4:23pm
F-3ASR
EX-4.3
8ndsd 93v
28 Mar 19
Automatic shelf registration (foreign)
9:09am
F-3ASR
EX-5.1
jl4b 72gxk
28 Mar 19
Automatic shelf registration (foreign)
9:09am
F-3ASR
EX-4.2
bux3bxy
28 Mar 19
Automatic shelf registration (foreign)
9:09am
6-K
EX-99.1
kyl5v
6 Feb 19
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:35am